Selecta Biosciences Garners $9,350,000 New Financing

  • Feed Type
  • Date
    6/18/2014
  • Company Name
    Selecta Biosciences
  • Mailing Address
    480 Arsenal St. Building One Watertown, MA 02472 USA
  • Company Description
    Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
  • Website
    http://www.selectabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $9,350,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Selecta continues to advance key immune activation programs, with newly-announced funding totaling $9.35 million from the Bill & Melinda Gates Foundation and NIH/NIDA.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy